Department of Health Abu Dhabi

What Department of Health Abu Dhabi does

The Department of Health Abu Dhabi (DoH) is the government regulatory authority for the healthcare sector in the Emirate of Abu Dhabi, established in 2007 and operating under the Abu Dhabi Government. It oversees a healthcare ecosystem comprising 65+ hospitals, 770+ clinics, 1,520+ medical centers, 8,900+ inpatient beds, and 950+ pharmacies, regulating facility licensing, professional qualifications, clinical standards, and public health. DoH serves the Abu Dhabi population through population health monitoring, preventive screening programs (including the multi-cancer early detection blood test priced AED 7,000-8,000 for residents aged 40+ via the IFHAS program), and digital service delivery via the TAMM government platform. It also acts as a strategic counterparty and regulator for global pharmaceutical, biotech, and health technology firms seeking to operate in the emirate.

DoH's technology stack centers on integrated health data platforms: Malaffi (health information exchange connecting all emirate providers), the Unified Medical Operations Command Centre (AI-powered monitoring and emergency response), Shafafiya (pricing transparency and clinical costing), and the Tableegh public health platform. The Emirati Genome Programme has sequenced nearly 1 million genomes, one of the largest population genomics efforts globally, integrated with clinical records via Malaffi and now linked to the Abu Dhabi Biobank capable of storing up to 5 million biological samples and 100,000+ cord blood samples. AI capabilities span predictive risk profiling for 14 diseases, Rasid AI environmental surveillance across 100+ sites, generative AI drug design (Insilico's Chemistry42 platform producing UAE's first AI-designed preclinical candidate in six months), and the world's first intelligent surgical network with Johnson & Johnson deployed across Cleveland Clinic Abu Dhabi, PureHealth, Mediclinic, and NMC.

As a government entity, DoH is primarily funded through public allocation rather than commercial revenue, with limited licensing and compliance-related fees. Its market-development activities focus on attracting global life sciences investment into the HELM (Health, Endurance, Longevity, Medicine) cluster, which combines Abu Dhabi Investment Office, MBZUAI, and Hub71 to support research, clinical development, and commercialization. Strategic partnerships with Sanofi (vaccine innovation centre), MSD (regional logistics hub), Johnson & Johnson (surgical AI), Boehringer Ingelheim, GSK, Mammoth Biosciences, Arbor Biotechnologies, Children's Hospital of Philadelphia, Fred Hutchinson Cancer Center, ŌURA, Insilico Medicine, and Biocom California position DoH as a gateway to Middle Eastern and regional markets while advancing the emirate's healthcare research and innovation agenda.

Name

Department of Health Abu Dhabi

Legal name

Department of Health – Abu Dhabi (DoH)

Website

https://doh.gov.ae

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

501–1,000 employees

Short description

The Department of Health Abu Dhabi is the government regulatory authority overseeing the healthcare sector in the Emirate of Abu Dhabi, managing licensing, digital health infrastructure, the Emirati Genome Programme, and the HELM life sciences cluster for population health and global innovation partnerships.

Ownership category

akta.pro rank

Product category

Healthcare Regulation

NAICS

General Medical and Surgical Hospitals (6221), Specialty (except Psychiatric and Substance Abuse) Hospitals (622310)

SIC

Services-Hospitals (8060), Hospital & Medical Service Plans (6324)

akta.pro primary industry

Medicare Advantage HMOs (HMO/HMO-POS) (HLAEAMAH)

akta.pro secondary industry

Specialty HMOs (e.g., Behavioral Health, Dental, Vision) (HLAEAMAJ)

Keywords

• Healthcare regulation
• Public health services
• Health facility licensing
• Health information exchange
• Population genomics programs

Headquarters

HQ city

Abu Dhabi

HQ country

United Arab Emirates

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Technology or R&D

Revenue model

1. Healthcare Regulatory Services: DoH functions as the regulatory body for Abu Dhabi's healthcare sector, overseeing licensing, inspections, compliance audits, and enforcement of healthcare standards.
2. Healthcare Facility Licensing and Compliance: DoH conducts 4,540+ licensing audit rounds annually and compliance audits, issuing corrective actions and enforcing standards across healthcare facilities.
3. Healthcare Services Delivery: DoH oversees healthcare delivery through designated Centers of Excellence treating complex cases including transplants and advanced treatments.

Pricing tiers

Go-to-market motion2 records

Distribution channels5 records

Marketing channels6 records

Core offering

Department of Health Abu Dhabi (DoH) is the regulatory authority overseeing the healthcare sector of the Emirate of Abu Dhabi. It licenses and inspects healthcare facilities, enforces quality and safety standards, monitors population health, and runs digital health platforms (Malaffi health information exchange, Shafafiya clinical costing, Tableegh public health platform). It also operates flagship programs such as the Emirati Genome Programme, Abu Dhabi Biobank, Centres of Excellence for complex care, and the HELM life sciences cluster.

Product overview

Department of Health Abu Dhabi operates as a regulatory body overseeing the healthcare sector in Abu Dhabi, managing a comprehensive ecosystem of digital health platforms and programs. The core digital infrastructure includes Malaffi (health information exchange), Tableegh (public health platform), Shafafiya (pricing transparency), and the Unified Medical Operations Command Centre (AI-powered health monitoring). Major initiatives include the Emirati Genome Programme (850,000+ genomes sequenced), Abu Dhabi Biobank (biological sample storage), and the HELM (Health, Endurance, Longevity, Medicine) life sciences cluster. Quality and accreditation programs include Muashir/Jawda (quality metrics), AAMEN (facilities accreditation), and Hospital Accreditation Program. Research support is provided through the Research and Innovation Center and the Healthcare Research and Innovation Grant. The DoH also oversees specialized Centres of Excellence for complex medical cases, and operates various eServices through the TAMM government services platform for licensing, insurance, and public services.

Differentiator

Problem solved

Functional benefit

Brands

• Emirati Genome Programme: Population genomics program that has sequenced nearly one million genomes to support precision medicine
• Malaffi
• HELM Cluster
• Sahatna
• Unified Medical Operations Command Centre (UMOC)
• Abu Dhabi Biobank

Products and services

• Malaffi Health Information Exchange Abu Dhabi's unified health information exchange platform connecting all healthcare providers across the emirate to share patient clinical records and genomic data for coordinated care. Targeted at healthcare facilities and providers in Abu Dhabi.
• Shafafiya Healthcare pricing transparency and clinical costing platform enabling standardized pricing management, cost analysis, and reporting across healthcare facilities in Abu Dhabi. For healthcare facilities and payers.
• Tableegh Public Health Platform Abu Dhabi Public Health platform for population health management, disease surveillance, and coordination of public health programs across the emirate. For public health stakeholders and residents.
• ADEMSIS (Emergency Medical Services Information System) Unified framework for collecting and managing emergency medical services data across the emirate, supporting emergency response coordination. For EMS providers and health authorities.
• Unified Medical Operations Command Centre (UMOC) AI-enabled operational command center integrating clinical records, genetic data, and wearable device information for real-time incident detection, predictive analytics, and emergency response across Abu Dhabi's health system.
• Emirati Genome Programme Population-scale genomics program having sequenced 850,000+ genomes to understand genetic foundations of health and disease for precision medicine and research partnerships. For residents, researchers, and life sciences partners.
• Abu Dhabi Biobank State-of-the-art biological sample storage facility in Masdar City, developed with M42, storing 100,000+ cord blood samples and up to five million biological samples connected with longitudinal clinical, genomic, and lifestyle data. For researchers and clinical partners.
• Multi-Cancer Early Detection Blood Test (IFHAS) Multi-cancer early detection liquid biopsy blood test capable of identifying 50+ cancer types from a single blood sample, integrated into IFHAS health screening program for residents aged 40 and above.
• AAMEN Accreditation Program Healthcare facilities accreditation program ensuring compliance with quality and safety standards across Abu Dhabi's healthcare sector. For healthcare facilities seeking accreditation.
• Muashir (Jawda) Quality Metrics Program Healthcare quality metrics and excellence program that measures provider performance and incentivizes care quality, with initial focus on fertility services. For healthcare providers and quality teams.
• Centre of Excellence Program Designated specialized medical centers treating complex medical cases including lung transplants, robot-assisted dual kidney transplants, and minimally invasive aneurysm treatments, reducing need for overseas travel. For residents requiring advanced specialty care.
• Research and Innovation Center Central hub for healthcare research coordination, innovation funding, and support for clinical trials and scientific advancement in Abu Dhabi. For researchers, innovators, and clinical trial sponsors.
• Abu Dhabi Healthcare Research and Innovation Grant Funding program supporting local healthcare researchers, innovators, and entrepreneurs to enhance clinical research capabilities and foster local solutions. For researchers and startups.
• HELM Cluster (Health, Endurance, Longevity and Medicine) Life sciences innovation cluster bringing together research, investment, commercial applications, and healthcare delivery in Abu Dhabi's integrated ecosystem. For life sciences companies, investors, and research institutions.
• Future Health Challenge Abu Dhabi-led global health technology competition awarding funding to early detection and population health sensing solutions from innovators worldwide. For health technology teams globally.

Quantifiable outcome

• 60% reduction in overseas treatment cases
• +7 more outcomes

Named customers6 records

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability14 records

Feature9 records

Partnerships

23 partnerships are on record, tiered core.

• Boehringer IngelheimcoreStrategic or Co-development Partner · 26 June 2026Strategic collaboration to leverage Abu Dhabi's advanced genomics ecosystem to support precision medicine. Focus areas include cardiovascular diseases, diabetes, oncology, rare diseases, neurological disorders, metabolic diseases, fibrotic diseases, ophthalmology, and immune-related conditions.
• Arbor BiotechnologiescoreStrategic or Co-development Partner · 26 June 2026MoU to advance gene-editing therapies for rare and genetic diseases. Partnership explores opportunities to enhance R&D and clinical development in gene editing, support development of innovative treatments, and strengthen scientific and clinical capabilities.
• Mammoth BiosciencescoreStrategic or Co-development Partner · 25 June 2026Partnership with M42 and Mammoth Biosciences to develop CRISPR gene-editing therapies for rare and inherited diseases. Leverages insights from Emirati Genome Programme, plans to introduce Mammoth's lead clinical candidate MB-111 into Abu Dhabi's clinical research ecosystem, and establish advanced therapy manufacturing capabilities including lipid nanoparticle production.
• Children's Hospital of Philadelphia (CHOP)coreStrategic or Co-development Partner · 24 June 2026MoU to advance gene editing capabilities for rare diseases. CHOP's gene therapy experts will provide specialized training to Abu Dhabi clinician-scientists in base-editing therapies targeting liver metabolic disorders, genetic clotting disorders, urea cycle disorders, and CNS conditions. Abu Dhabi contributes population-scale genomics with nearly 1 million genomes sequenced.
• MSD (Merck & Co., Inc.)coreStrategic or Co-development Partner · 24 June 2026Partnership to explore establishing a regional logistics hub within HELM cluster. Subject to regulatory approvals, the hub would support distribution of MSD's broad product portfolio across regional markets, strengthening supply chain resilience and improving patient access to innovative therapies.
• Biocom CaliforniacoreStrategic or Co-development Partner · 23 June 2026Strategic partnership to create a formal gateway between Abu Dhabi's and California's life sciences ecosystems. Connects Abu Dhabi's HELM cluster with California's renowned bioscience community, enabling innovators, researchers, and investors to access both markets for developing, validating, and scaling health solutions.
• SanoficoreStrategic or Co-development Partner · 22 June 2026MoU to establish a vaccine innovation center in Abu Dhabi. Partnership focuses on AI-enabled vaccine discovery, mRNA research, clinical development, and advanced manufacturing within HELM cluster. Aims to strengthen regional and global health preparedness while developing local scientific talent.
• Future Health ChallengecoreStrategic or Co-development Partner · 22 May 2026Abu Dhabi-led initiative at 79th World Health Assembly awarding $300,000 to three global health technology teams (ThinkMD, Vector Control Innovations, Huna) for early detection and population health sensing solutions from 393 submissions across 68 countries.
• Johnson & JohnsoncoreStrategic or Co-development Partner · 21 May 2026Launch of global surgical intelligence network, first-of-its-kind globally. Using J&J's Polyphonic™ digital ecosystem with technology partners AWS and NVIDIA, deploying AI across operating rooms at Cleveland Clinic Abu Dhabi, PureHealth, Mediclinic Group, and NMC Healthcare. Aims to build structured, anonymized surgical dataset for AI development.
• Opus GeneticscoreStrategic or Co-development Partner · 19 May 2026Support for phase 1/2 clinical trial for OPGx-MERTK gene therapy targeting MERTK-related retinitis pigmentosa. Trial conducted at Cleveland Clinic Abu Dhabi with clinical operations by M42's IROS division and funding from Authority of Social Contribution - Ma'an.
• Authority of Social Contribution - Ma'ancoreStrategic or Co-development Partner · 19 May 2026Government entity providing funding support for healthcare research and innovation, including funding for Opus Genetics gene therapy trial and Healthcare Research and Innovation Grant programs.
• Fred Hutchinson Cancer CentercoreStrategic or Co-development Partner · 14 May 2026MoU for collaboration on cancer research and personalized prevention. Combines Abu Dhabi's clinical and genomic data infrastructure, AI capabilities, and governed data environments with Fred Hutch's globally recognized research expertise.
• Abu Dhabi Investment Office (ADIO)coreStrategic or Co-development Partner · 10 May 2026Government entity supporting life sciences ecosystem development, investing in health innovation infrastructure, and facilitating partnerships between Abu Dhabi and international healthcare companies.
• Abu Dhabi Stem Cells CentercoreStrategic or Co-development Partner · 10 May 2026Partnership for development of gene therapies and stem cell treatments, including administration of UAE's first gene therapy (CASGEVY) for genetic blood disorders.
• ŌURAcoreStrategic or Co-development Partner · 7 May 2026Joint research programme to study how continuous wearable data can advance preventive health. Initially focusing on women's health and cardiometabolic risk, integrating Abu Dhabi's longitudinal health data with ŌURA's real-time wearable insights. Supported by joint data governance framework.
• Insilico MedicinecoreStrategic or Co-development Partner · 24 April 2026Support for ISM0387 nomination as UAE's first AI-designed preclinical candidate, an MTA-cooperative PRMT5 inhibitor targeting glioblastoma. Discovered using Pharma.AI platform at Abu Dhabi Generative AI and Quantum Computing R&D Center.
• M42coreStrategic or Co-development Partner · 23 April 2026Integrated health intelligence company operating Malaffi health information exchange, Emirati Genome Programme sequencing, Rasid AI surveillance, and Abu Dhabi Biobank initiative in partnership with DoH.
• Cleveland Clinic Abu DhabicoreStrategic or Co-development Partner · 22 April 2026Major quaternary care hospital participating in Opus Genetics gene therapy trial, surgical AI network with Johnson & Johnson, and various DoH clinical programs.
• CoreXcoreStrategic or Co-development Partner · 7 February 2026Abu Dhabi-based bio-intelligence company building population biobank using Ouris-AI system to analyze medication effects across ethnic groups. Works with DoH and Institute for Healthier Living Abu Dhabi to develop precision prescriptions for Middle Eastern communities.
• World Economic ForumcoreStrategic or Co-development Partner · 23 January 2026Extended partnership at Davos 2026 as Global Pathfinder within WEF's Digital Healthcare Transformation Initiative. Abu Dhabi's system connects clinical, genomic, lifestyle, and environmental data to predict health risks at population scale.
• Hub71+ Life SciencescoreStrategic or Co-development Partner · 21 October 2025Launch of Hub71+ Life Sciences ecosystem with 12 founding partners including DoH and Emirates Drug Establishment. Provides startups direct access to regulators, hospitals, investors, and industry partners with regulatory support and funding opportunities.
• HELM Cluster Partners (ADIO, MBZUAI, Hub71)coreStrategic or Co-development Partner · 15 April 2025Abu Dhabi Investment Office, DoH, Mohamed bin Zayed University of Artificial Intelligence, and Hub71 partnered under HELM cluster to advance AI-driven life sciences. Provides infrastructure for analyzing complex healthcare data, accelerate IP development, and support commercialization of AI-powered healthcare solutions.
• GSKcoreStrategic or Co-development Partner · 15 April 2025MoU signed between UAE's Department of Health and Abu Dhabi Investment Office with GSK to establish a cancer research institute in Abu Dhabi focused on genomics integration.

Scale indicators7 records

Recent moves8 records

Expansion highlights8 records

Regional players

• National Health Regulatory Authority (Bahrain): Bahrain's healthcare regulator with licensing, facility inspection and health professional oversight responsibilities. Smaller-scale regional peer to DoH with comparable regulatory functions but a much smaller population base.

Others

• M42: Abu Dhabi-based integrated health intelligence company operating Malaffi, the Emirati Genome Programme sequencing, Rasid AI surveillance, and the Abu Dhabi Biobank in partnership with DoH. Closely intertwined with DoH's digital and genomics infrastructure, and effectively the operating arm of several DoH flagship programmes.
• PureHealth: Abu Dhabi's largest integrated healthcare platform and a key partner across DoH's surgical AI network, Centres of Excellence, and digital health initiatives. Comparable as a regulated entity under DoH's authority and as an ecosystem operator within HELM.

Emerging players

• UK Biobank: Large-scale biomedical database with deep genetic, lifestyle and health linkage from 500,000+ participants. Comparable to the Abu Dhabi Biobank + Malaffi + Genome Programme combination as a population-scale research asset, though operated as a charitable rather than government authority.
• Genomics England: UK government-backed initiative that sequenced 100,000+ whole genomes from NHS patients for research and clinical use. Directly comparable to DoH's Emirati Genome Programme in mandate (population genomics for precision medicine), though smaller in scale (~1M vs ~100K).

Direct peers

• Dubai Health Authority: Dubai's healthcare sector regulator and operator, with overlapping mandate in licensing, facility oversight, health data platforms (NABIDH, SALAMA), and population health programmes. Directly comparable to DoH as the parallel health authority for the neighbouring emirate within the UAE.

Broad incumbents

• Saudi Food and Drug Authority (SFDA): National regulator of pharmaceuticals, biologics and medical devices in Saudi Arabia. Comparable to DoH's EDE on the drug/biologic approval side and to DoH's broader healthcare oversight remit. Competes with Abu Dhabi for regional pharma R&D and clinical trial placement.
• National Health Service England (NHS England): UK public health system combining service delivery, regulation, and digital health programmes at population scale. Comparable to DoH on the integrated regulator-plus-operator model, and a partner reference for AI-in-healthcare deployments (e.g., Federated Data Platform).
• Singapore Ministry of Health (MOH): National health authority overseeing public healthcare, licensing, and biomedical strategy in Singapore. Comparable to DoH given both jurisdictions pursue a "regional/global health hub" strategy backed by strong regulatory frameworks and life sciences clusters (Biopolis).
• Ministry of Health and Prevention UAE: Federal health authority for the UAE overseeing national policy, federal licensing, and preventive health. Comparable to DoH in mandate (regulation, population health, licensing) but with broader national rather than emirate-level scope.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/dohsocial
• Facebookfacebook.com/dohSocial

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Department of Health Abu Dhabi